T
Thomas Martin
Researcher at University of California, San Francisco
Publications - 311
Citations - 17918
Thomas Martin is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Exocytosis. The author has an hindex of 73, co-authored 242 publications receiving 15771 citations. Previous affiliations of Thomas Martin include Institut national de la recherche agronomique & University of Western Australia.
Papers
More filters
Journal ArticleDOI
Voriconazole Is Safe and Effective as Prophylactic Antifungal Therapy Following Allogeneic Transplantation.
Thomas Martin,Ryan B. O'Malley,Joe Guglielmo,Neal Fischbach,Lloyd E. Damon,Willis H. Navarro,L. Kaplan,Richard Jacobs,John Andrews,Charles A. Linker +9 more
TL;DR: In this cohort of 72 patients, VORI appears safe and effective as prophylaxis for alloBMT, and overall, voriconazole appeared well tolerated.
Journal ArticleDOI
Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial
Paul G. Richardson,Jeffrey L. Wolf,Andrzej Jakubowiak,Jeffrey A. Zonder,Sagar Lonial,David Irwin,John J. Densmore,Amrita Krishnan,Noopur Raje,Michael Bar,Robert L. Schlossman,Irene M. Ghobrial,Nikhil C. Munshi,Thomas Martin,Jacob P. Laubach,Jeffrey P. Allerton,Teru Hideshima,Peter Sportelli,L. Gardner,Kenneth C. Anderson +19 more
TL;DR: A phase I/II study of perifosine + bortezomib (Vel) +/− dexamethasone (Dex) which demonstrated encouraging safety and preliminary clinical activity in relapsed and refractory multiple myeloma patients (pts), including overall response rate, progression-free survival (PFS) and overall survival (OS) is reported.
Journal ArticleDOI
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Shaji Kumar,Natalie S. Callander,Kehinde Adekola,Larry D. Anderson,Muhamed Baljevic,Erica L. Campagnaro,Jorge J. Castillo,Caitlin Costello,Christopher D'Angelo,Srinivas Devarakonda,Noura B. Elsedawy,Alfred L. Garfall,Kelly N. Godby,Jens Hillengass,Leona Holmberg,Myo Htut,Carol Ann Huff,Malin Hultcrantz,Yubin Kang,Sarah Larson,Hans C. Lee,Michaela Liedtke,Thomas Martin,James L. Omel,Aaron S. Rosenberg,Douglas W. Sborov,Jason Valent,R. Berardi,Rashmi Kumar +28 more
TL;DR: The NCCN Guidelines for SLCA provide recommendations for workup, diagnosis, and treatment of primary systemic light chain amyloidosis (SLCA) as discussed by the authors .
Journal ArticleDOI
Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
Luciano J. Costa,Parameswaran Hari,Jesus G. Berdeja,Valerio De Stefano,Francesca Gay,B. Hooper,M. Bartlett,Anja Haltner,Emily Rosta,Shaji Kumar,Thomas Martin,Maria-Victoria Mateos,Philippe Moreau,Saad Z. Usmani,Yunsi Olyslager,Jordan M. Schecter,Tito Roccia,A. Garrett,Sam Lee,Tonia Nesheiwat,Lida Bubuteishvili Pacaud,Changwei Zhou,Imtiaz A. Samjoo,Yi Lin,Joris Diels,Satish Valluri,Katja Weisel +26 more
TL;DR: Evaluating multiple indirect comparisons, cilta-cel demonstrated a significantly superior advantage over PCT, highlighting its effectiveness as a therapy in patients with triple-class exposed RRMM.
Proceedings ArticleDOI
Abstract 5469: SAR650984, an anti-CD38 antibody, shows anti-tumor activity in a preclinical model of multiple myeloma.
TL;DR: SAR650984, an anti-CD38 antibody, shows anti-tumor activity in a preclinical model of multiple myeloma and demonstrates that targeting CD38 with SAR650983 has potential to impact MM disease.